Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SPRINTEC vs ALYACEN 7/7/7
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of ethinyl estradiol and norgestimate suppresses gonadotropin release, inhibiting ovulation and altering cervical mucus and endometrium to prevent pregnancy.
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
Prevention of pregnancy,Treatment of moderate acne vulgaris in women at least 15 years of age who have achieved menarche and are seeking an oral contraceptive
Prevention of pregnancy
One tablet (0.25 mg norgestimate, 0.035 mg ethinyl estradiol) orally once daily at the same time each day for 21 days, followed by 7 days of placebo tablets.
ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.
Ethinyl estradiol: 13 ± 3 hours (variable, influenced by CYP3A4 activity); Norgestimate: 1.5-2 hours (rapidly converted to norelgestromin); Norelgestromin: 12-20 hours (active metabolite); clinical context: dosing interval of 24 hours supports once-daily administration.
Terminal elimination half-life is 14 hours (range 12-16 h) in healthy adults; prolonged to 24-30 h in moderate renal impairment (Cr Cl 30-50 m L/min).
Ethinyl estradiol is metabolized primarily by CYP3A4; norgestimate is rapidly metabolized to norelgestromin and norgestrel via first-pass metabolism.
Norethindrone: primarily hepatic via reduction and conjugation, with CYP3A4 involvement. Ethinyl estradiol: primarily via CYP3A4, also undergoes sulfation and glucuronidation.
Renal: approximately 50-60% (metabolites, primarily glucuronide conjugates), Fecal: approximately 30-40% (biliary excretion of metabolites), with minimal unchanged drug in urine (<5%).
Renal: ~50% (unchanged drug); Fecal: ~20% (via bile); Biliary: ~30% (metabolites). Total clearance is 12 L/h.
Ethinyl estradiol: >97% bound to albumin; Norgestimate/norelgestromin: 99% bound to albumin and sex hormone-binding globulin (SHBG).
98% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
Ethinyl estradiol: 2.5-4.0 L/kg; Norgestimate: not determined (extensive tissue distribution); clinical meaning: reflects distribution into total body water and tissues.
0.35 L/kg (total body water distribution); in obesity, Vd increases to 0.5 L/kg due to lipophilicity.
Ethinyl estradiol: 38-48% due to first-pass metabolism; Norgestimate: 100% (prodrug, rapidly hydrolyzed in gut wall and liver).
Oral: 85% (with high-fat meal reduces to 70%); Sublingual: 90%.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment; use caution.
Contraindicated in patients with severe renal impairment (Cr Cl <30 m L/min) or acute renal failure due to drospirenone's antimineralocorticoid activity. No dose adjustment recommended for mild to moderate impairment (Cr Cl ≥30 m L/min).
Contraindicated in patients with acute or chronic hepatic dysfunction (Child-Pugh class B or C). No data for mild impairment; use with caution.
Contraindicated in patients with acute hepatic disease, hepatic tumors, or impaired liver function (Child-Pugh class B or C). Discontinue if jaundice or pruritus develops. No dose adjustment for Child-Pugh class A.
Safety and efficacy have not been established in postmenarchal pediatric patients. Use after first menses; dosing same as adults.
Not indicated for use in pediatric patients before menarche. Safety and efficacy in postmenarchal adolescents are expected to be similar to adults; dose is same as adults.
Not indicated for use in postmenopausal women. No specific dose adjustment needed for elderly patients beyond contraindications.
Not indicated for use in postmenopausal women. No recommendations for geriatric population due to lack of indication.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptive use. Risk increases with age (>35 years) and number of cigarettes smoked. Women over 35 who smoke should not use combined oral contraceptives.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives (COCs). Risk increases with age and amount smoked (especially >15 cigarettes/day). Women over 35 who smoke should not use COCs.
Increased risk of thromboembolic disorders,Increased risk of myocardial infarction and stroke, especially in smokers,Increased risk of hepatic neoplasia,Elevated blood pressure,Gallbladder disease,Carbohydrate and lipid effects,Ocular lesions,Hereditary angioedema,Chloasma
Thrombotic disorders (thrombophlebitis, pulmonary embolism, cerebral hemorrhage, myocardial infarction),Cerebrovascular disease,Carcinoma of the breast or reproductive organs,Hepatic adenoma or carcinoma,Ocular lesions (retinal thrombosis, papilledema),Gallbladder disease,Carbohydrate/lipid effects,Elevated blood pressure,Hereditary angioedema,Chloasma,Hepatic impairment
Thrombophlebitis or thromboembolic disorders,Cerebrovascular or coronary artery disease,Known or suspected breast cancer,Estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component
Breast cancer (current or history),Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Current or history of thrombotic disorders (DVT, PE, stroke, MI),Cerebrovascular or coronary artery disease,Valvular heart disease with complications,Severe hypertension,Diabetes with vascular disease,Headaches with focal neurological symptoms (e.g., migraine with aura),Major surgery with prolonged immobilization,Known thrombophilia (e.g., Factor V Leiden, prothrombin mutation, protein S/C deficiency),Active liver disease (tumors, hepatitis, cirrhosis),Uncontrolled hypertension,Smoking (if age >35),Hypersensitivity to any component
Avoid grapefruit juice as it may increase estrogen levels and risk of adverse effects. No other significant food interactions are known; maintain consistent dietary habits to minimize gastrointestinal side effects.
Grapefruit and grapefruit juice may increase ethinyl estradiol levels, potentially increasing side effects. St. John's wort (herbal supplement) can reduce contraceptive efficacy. No other significant food interactions; however, maintaining a stable intake of vitamin C and folate is generally recommended.
FDA Pregnancy Category X. Use contraindicated in pregnancy. First trimester: Major congenital anomalies including cardiovascular and limb defects; increased risk of neural tube defects. Second and third trimesters: Fetal genital abnormalities in females (diethylstilbestrol-like effect); potential for long-term reproductive tract changes. Postnatal: Possible increased risk of neurodevelopmental issues.
ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does not warrant termination. Second and third trimesters: Avoid use due to potential adverse effects on fetal development, including feminization of male fetuses and potential for congenital anomalies from progestin. Postnatal: Possible long-term effects on reproductive development.
Excreted in human breast milk with milk-to-plasma ratio approximately 0.5. Potential adverse effects in nursing infant including jaundice and breast enlargement. Use during lactation not recommended unless clearly necessary. May reduce milk production and quality.
Contraindicated in breastfeeding. Ethinylestradiol reduces milk quantity and quality. Norethindrone is excreted in low amounts (M/P ratio approximately 0.3-0.4). However, combination oral contraceptives are not recommended during lactation due to estrogen effects on milk production.
No dose adjustments approved; contraindicated in pregnancy. Pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) could reduce efficacy if used, but use is contraindicated.
ALYACEN 7/7/7 is contraindicated in pregnancy; no dose adjustments are applicable as use is not recommended. Pharmacokinetic changes in pregnancy (increased clearance of steroids) would theoretically require higher doses, but due to fetal risks, alternative therapies should be used.
SPRINTEC (ethinyl estradiol/norgestimate) is a combined oral contraceptive. Prescribe with caution in women with migraine with aura due to increased stroke risk. If a dose is missed, take as soon as remembered; if >24 hours late, use backup contraception for 7 days. Monitor blood pressure at initiation and annually. Discontinue if pregnancy is suspected or confirmed. Advise that antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy.
ALYACEN 7/7/7 is a triphasic oral contraceptive containing ethinyl estradiol and norgestimate. The 7/7/7 regimen refers to the varying doses of norgestimate across three 7-day phases (0.18 mg, 0.215 mg, 0.25 mg) with a fixed 0.025 mg ethinyl estradiol. Use consistent 7-day placebo interval. Consider increased risk of venous thromboembolism (VTE) in patients with BMI >30, smoking >15 cigarettes/day, or age >35. Monitor for breakthrough bleeding, especially during the first 3 cycles. Avoid in patients with migraine with aura, uncontrolled hypertension, or history of DVT/PE. Drug interactions with CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce efficacy; consider backup contraception.
Take one tablet daily at the same time each day, in the order directed on the pill pack.,If you miss a pill, refer to the package insert or consult your healthcare provider; use backup contraception as directed.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding; these often improve within a few cycles.,Seek immediate medical attention for symptoms of blood clots: sudden leg pain/swelling, chest pain, shortness of breath, or sudden severe headache.,Inform your provider about all medications, including over-the-counter drugs and herbal supplements, especially St. John's Wort.
Take one pill daily at the same time each day, in the order specified on the pack (active pills followed by placebo).,If you miss a pill, follow the package instructions; missing pills increases pregnancy risk, especially if placebo week is extended.,Common side effects include nausea, headache, breast tenderness, and spotting, which usually improve after 2-3 cycles.,Seek immediate medical attention for severe abdominal pain, chest pain, shortness of breath, leg pain/swelling, or severe headache.,This medication does not protect against HIV/AIDS or other sexually transmitted infections (STIs).,Inform your healthcare provider if you smoke, as smoking increases risk of serious cardiovascular side effects, especially if over 35 years.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SPRINTEC vs ALYACEN 7/7/7, answered by our medical review team.
SPRINTEC is a Oral Contraceptive that works by Combination of ethinyl estradiol and norgestimate suppresses gonadotropin release, inhibiting ovulation and altering cervical mucus and endometrium to prevent pregnancy.. ALYACEN 7/7/7 is a Oral Contraceptive that works by Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SPRINTEC and ALYACEN 7/7/7 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SPRINTEC is: One tablet (0.25 mg norgestimate, 0.035 mg ethinyl estradiol) orally once daily at the same time each day for 21 days, followed by 7 days of placebo tablets.. The standard adult dose of ALYACEN 7/7/7 is: ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SPRINTEC and ALYACEN 7/7/7 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SPRINTEC is classified as Category C. FDA Pregnancy Category X. Use contraindicated in pregnancy. First trimester: Major congenital anomalies including cardiovascular and limb defects; increased risk of neural tube def. ALYACEN 7/7/7 is classified as Category C. ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does n. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.